P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended

P2/3, N=36, Not yet recruiting, Merck Sharp & Dohme LLC

These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.

P2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P2/3, N=2, Not yet recruiting, Merck Sharp & Dohme LLC

P2, N=90, Not yet recruiting, SWOG Cancer Research Network

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.

P1, N=70, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P2/3, N=340, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2029 --> Oct 2033 | Trial primary completion date: Feb 2029 --> Oct 2033

P2, N=71, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Dec 2026 --> Jun 2027